FIELD: medicine.
SUBSTANCE: using the human placental perfusate cells in preparing a therapeutic agent for suppressing tumour cells proliferation in an individual having the tumour cells, wherein the placental perfusate cells represent a collection of nuclear cells of the placental perfusate. Using natural killer cells of CD56+, CD16- recovered from the placenta for preparing the therapeutic agent for suppressing the tumour cells proliferation in the individual having the tumour cells. Using the combined natural killer cells in preparing the therapeutic agent for suppressing the tumour cells proliferation in the individual having the tumour cells, wherein the above combined natural killer cells comprise the natural killer cells recovered from the placental perfusate, and the natural killer cells recovered from the umbilical blood, and wherein the umbilical blood is recovered from the placenta, which is used to prepare the above placental perfusate. A method for suppressing the tumour cells proliferation in vitro, involving the tumour cells contact to the human placental perfusate cells, wherein the placental perfusate cells represent the collection of the nuclear cells from the placental perfusate. The method for suppressing the tumour cells proliferation in vitro, involving the tumour cell contact to the number of the natural killer cells prepared of placental CD56+, CD16-. The method for suppressing the tumour cells proliferation in vitro, involving the tumour cells contact to the combined natural killer cells, wherein the above combined natural killer cells involve the natural killer cells recovered from the placental perfusate, and the natural killer cells recovered from the umbilical blood, and wherein the umbilical blood is recovered from the placenta, which is used for prepare the above placental perfusate. A composition applicable in suppressing the tumour cells proliferation, containing the recovered natural killer cells of CD56+, CD16-, wherein the above natural killer cells are recovered from the placental perfusate, and wherein the above natural killer cells make at least 50% cells in the composition.
EFFECT: placental perfusate cells and methods for using them enable suppressing the tumour cells proliferation effectively.
40 cl, 13 tbl, 6 ex, 11 dwg
Title | Year | Author | Number |
---|---|---|---|
SUPPRESSION OF TUMORS USING HUMAN PLACENTAL PERFUSATE AND AUXILIARY NATURAL KILLER CELLS ISOLATED FROM HUMAN PLACENTA | 2008 |
|
RU2781543C2 |
SUPPRESSION OF TUMORS USING HUMAN PLACENTA DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATING COMPOUNDS | 2010 |
|
RU2742171C2 |
TUMOUR SUPPRESSION WITH APPLICATION OF INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS OBTAINED FROM HUMAN PLACENTA | 2010 |
|
RU2642988C2 |
IMPROVED CELL COMPOSITION AND METHODS OF OBTAINING THEREOF | 2009 |
|
RU2563518C2 |
IMPROVED CELL COMPOSITION AND METHODS FOR ITS PREPARATION | 2009 |
|
RU2662676C1 |
TREATMENT OF DISEASE, DISORDERS OR PATHOLOGICAL CONDITIONS OF LUNGS WITH APPLICATION OF PLACENTAL CELLS | 2009 |
|
RU2570550C2 |
TREATING DISEASES, DISORDERS OR PATHOLOGICAL CONDITIONS OF THE LUNGS USING PLACENTAL CELLS | 2009 |
|
RU2732240C2 |
STROKE TREATMENT WITH APPLICATION OF ISOLATED PLACENTAL CELLS | 2009 |
|
RU2558778C2 |
METHOD FOR EXPANSION OF HUMAN NK CELLS USING FEEDER CELLS | 2021 |
|
RU2781777C2 |
METHOD OF PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH UNRESECTABLE TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2802141C1 |
Authors
Dates
2014-12-20—Published
2008-09-29—Filed